1. Background
2. Objectives
3. Methods
3.1. Specimen Collection and Samples Sources
3.2. Antimicrobial Susceptibility Testing
3.3. Compounds Sources
3.4. Determination of Bactericidal Activity of Nanometals, and Synthetic Peptides
3.5. Determination of Antimicrobial Synergism
3.6. Time- Kill Curve Assay
4. Results
4.1. Antimicrobial Susceptibility
| Antibiotics | K. pneumonia (No. of Isolates) | A. baumannii (No. of Isolates) | P. aeruginosa (No. of Isolates) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| R | I | S | R | I | S | R | I | S | |
| TIG | 30 | 0 | 70 | 0 | 10 | 90 | 50 | 10 | 40 |
| CAZ | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 |
| IMP | 100 | 0 | 0 | 100 | 0 | 0 | 100 | 0 | 0 |
| MEM | 90 | 10 | 0 | 100 | 0 | 0 | 100 | 0 | 0 |
| AK | 100 | 0 | 0 | 90 | 0 | 10 | 70 | 0 | 30 |
| CFO | 100 | 0 | 0 | ND | ND | ND | ND | ND | ND |
| GM | 100 | 0 | 0 | 90 | 0 | 10 | 90 | 10 | 0 |
| CPO | 100 | 0 | 0 | 100 | 0 | 0 | 90 | 0 | 10 |
| FO | 20 | 20 | 60 | ND | ND | ND | ND | ND | ND |
| CIP | 70 | 10 | 20 | 100 | 0 | 0 | 100 | 0 | 0 |
| ZOX | 100 | 0 | 0 | ND | ND | ND | 100 | 0 | 0 |
| NOR | 60 | 20 | 20 | ND | ND | ND | ND | ND | ND |
| FEP | 80 | 20 | 0 | 100 | 0 | 0 | ND | ND | ND |
| AZT | ND | ND | ND | 100 | 0 | 0 | 90 | 0 | 10 |
| PTZ | ND | ND | ND | 100 | 0 | 0 | 80 | 10 | 10 |
Abbreviations: AK, amikacin; CAZ, ceftazidime; CFO, cefoxitin; CPO, cefpirome; CIP, ciprofloxacin; FO, Fosfomycin; FEP, cefepime; GM, gentamicin; TIG, tigecycline; IMP, imipenem; I, intermediate; MEM, meropenem; NOR, norfloxacin; ND, not determined; R, resistance; S, sensitive; ZOX, ceftizoxime.
aAntibiotic sensitivity was determined in Muller-Hinton agar with inoculum concentration 1 ×106 CFU/ml.
4.2. Compounds Characterization
4.3. Antibacterial Activity of the Mastoparan-B, Indolicidin, ZnO NPs and TiO2 NPs
| Isolate No. | Mastoparan-B | Indolicidin | Nano-Tio2 | Nano-ZnO | ||||
|---|---|---|---|---|---|---|---|---|
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | |
| AB | ||||||||
| 1 | 4 | 4 | 16 | 16 | 640 | 640 | 80 | 80 |
| 2 | 4 | 4 | 8 | 32 | 640 | 640 | 80 | 80 |
| 3 | 4 | 8 | 16 | 16 | 320 | 320 | 40 | 80 |
| 4 | 4 | 4 | 32 | 32 | 640 | 640 | 160 | 320 |
| 5 | 4 | 4 | 16 | 16 | 640 | 640 | 320 | 320 |
| 6 | 16 | 32 | 32 | 64 | 1280 | 1280 | 80 | 80 |
| 7 | 4 | 4 | 16 | 16 | 1280 | 1280 | 80 | 80 |
| 8 | 4 | 4 | 32 | 32 | 640 | 1280 | 320 | 320 |
| 9 | 2 | 2 | 8 | 16 | 320 | 320 | 40 | 80 |
| 10 | 4 | 4 | 16 | 32 | 640 | 640 | 80 | 80 |
| KP | ||||||||
| 1 | 8 | 8 | 64 | 64 | 1280 | 1280 | 160 | 160 |
| 2 | 8 | 16 | 32 | 32 | 1280 | 1280 | 160 | 160 |
| 3 | 16 | 16 | 32 | 64 | 2560 | 2560 | 640 | 640 |
| 4 | 8 | 8 | 32 | 32 | 1280 | 1280 | 160 | 160 |
| 5 | 16 | 32 | 64 | 64 | 640 | 1280 | 320 | 320 |
| 6 | 8 | 8 | 32 | 32 | 1280 | 1280 | 80 | 160 |
| 7 | 8 | 8 | 32 | 64 | 1280 | 1280 | 320 | 320 |
| 8 | 8 | 8 | 64 | 64 | 2560 | 2560 | 640 | 640 |
| 9 | 4 | 4 | 32 | 32 | 1280 | 1280 | 160 | 160 |
| 10 | 4 | 4 | 32 | 32 | 640 | 640 | 160 | 160 |
| PS | ||||||||
| 1 | 32 | 32 | 64 | 128 | ≥ 2560 | ND | 2560 | 2560 |
| 2 | 32 | 32 | 64 | 64 | ≥ 2560 | ND | 2560 | 2560 |
| 3 | 64 | 64 | 128 | 128 | ≥ 2560 | ND | ≥2560 | ND |
| 4 | 32 | 64 | 64 | 64 | ≥ 2560 | ND | 1280 | 1280 |
| 5 | 64 | 64 | 128 | 128 | ≥ 2560 | ND | 2560 | 2560 |
| 6 | 128 | 128 | 128 | 256 | ≥ 2560 | ND | ≥2560 | ND |
| 7 | 32 | 32 | 64 | 64 | ≥ 2560 | ND | 2560 | 2560 |
| 8 | 32 | 32 | 128 | 128 | ≥ 2560 | ND | ≥2560 | ND |
| 9 | 64 | 64 | 128 | 128 | ≥ 2560 | ND | 1280 | 1280 |
| 10 | 32 | 64 | 64 | 64 | ≥ 2560 | ND | 2560 | 2560 |
Abbreviations: AB, A. baumannii; KP, K. pneumonia; MIC, mg/mL; MBC, mg/mL; ND, not determined; PS, P. aeruginosa.
aSterile M9 medium containing glucose as the source of carbon was used for metal oxide NPs and LB broth was used for peptides MIC determinations. MICs were performed in triplicate with a standard deviation of ± 0.2. Bacterial sample was used at 1 × 106 CFU/mL.
4.4. Synergism and Time-Kill Curves Analysis
| Nanoparticles and Peptides | Number of Isolate | FICs | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.18 | 0.25 | 0.31 | 0.37 | 0.5 | 0.53 | 0.56 | 0.62 | 0.75 | 1.0 | ||
| A. baumannii TiO2+ZnO | 7 | - | - | 1 | 3 | 3 | 1 | 3 | 5 | 3 | 1 |
| K. pneumonia TiO2+ZnO | 5 | - | - | 1 | 2 | 2 | 2 | 3 | 6 | 4 | - |
| A. baumannii MP + Indolicidin | 3 | - | - | - | 2 | 1 | - | - | 5 | 6 | 1 |
| K. pneumoniae MP + Indolicidin | 6 | - | - | - | 3 | 3 | - | 1 | 3 | 4 | 1 |
| P. aeruginosa MP + Indolicidin | 12 | 2 | 2 | 4 | 1 | 3 | 4 | 2 | 4 | - | 1 |
Abbreviations: FICs, Fractional inhibitory concentration indexes; MP, Mastoparan-B; Indo, Indolicidin.
aThe above values are in mg/mL. M9 containing glucose as source of carbon was used for nanometals and LB broth was used for peptides. 0.5 ≤ synergism, 0.5-1 = additive, 1- 4 = indifference, 4 ≥ antagonism. The results were repeated three times and similar observation was made. P ≤ 0.5 was considered statistically significant.
